Status:
UNKNOWN
Cognitive Remediation Therapy in Schizophrenia: Effects on Epigenetics
Lead Sponsor:
Hospital Clinic of Barcelona
Collaborating Sponsors:
National Alliance for Research on Schizophrenia and Depression
Instituto de Salud Carlos III
Conditions:
Schizophrenia
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
This study is a randomised and controlled trial that aims to investigate whether Cognitive Remediation Therapy (CRT) can modulate epigenetic mechanisms by changing methylation levels of BDNF gene in p...
Detailed Description
OBJECTIVES: To investigate whether Cognitive Remediation Therapy (CRT) can modulate epigenetic mechanisms by changing methylation levels of BDNF gene. It also aims to test whether BDNF valine-66-methi...
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia according to DSM-5 and confirmed by the semi-structured interview (SCID) for the axis 1.
- Presence of cognitive impairment confirmed by the neuropsychological battery
- Stable symptomatology at least during the last six months and the estimation of not modifying pharmacological antipsychotic treatment .
Exclusion
- Presence of organic-cerebral affectation due to neurological or traumatic conditions
- Antipsychotic dose change \>10%
- Abuse of psychotropic substances
- Presence of other psychiatric symptomatology
Key Trial Info
Start Date :
January 3 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 15 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04278027
Start Date
January 3 2017
End Date
June 15 2020
Last Update
February 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Clinic de Barcelona
Barcelona, Spain, 08036